Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly dulaglutide versus placebo in pediatric type 2 diabetes
2016-000361-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dulaglutide with Placebo (2 arms). Primary endpoint: Change from baseline in HbA1c. Started Feb 2017; status: completed.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000361-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000361-22.